261 related articles for article (PubMed ID: 31992444)
21. Borderline and locally advanced pancreatic adenocarcinoma margin accentuation with intraoperative irreversible electroporation.
Kwon D; McFarland K; Velanovich V; Martin RC
Surgery; 2014 Oct; 156(4):910-20. PubMed ID: 25239345
[TBL] [Abstract][Full Text] [Related]
22. Intraoperative Pancreatic Neck Margin Assessment During Pancreaticoduodenectomy for Pancreatic Adenocarcinoma in the Era of Neoadjuvant Therapy: A Multi-institutional Analysis from the Central Pancreatic Consortium.
Kelly KN; Macedo FI; Seaton M; Wilson G; Hammill C; Martin RC; Maduekwe UN; Kim HJ; Maithel SK; Abbott DE; Ahmad SA; Kooby DA; Merchant NB; Datta J
Ann Surg Oncol; 2022 Sep; 29(9):6004-6012. PubMed ID: 35511392
[TBL] [Abstract][Full Text] [Related]
23. The impact of resection margin status and postoperative CA19-9 levels on survival and patterns of recurrence after postoperative high-dose radiotherapy with 5-FU-based concurrent chemotherapy for resectable pancreatic cancer.
Kinsella TJ; Seo Y; Willis J; Stellato TA; Siegel CT; Harpp D; Willson JK; Gibbons J; Sanabria JR; Hardacre JM; Schulak JP
Am J Clin Oncol; 2008 Oct; 31(5):446-53. PubMed ID: 18838880
[TBL] [Abstract][Full Text] [Related]
24. Neoadjuvant therapy may lead to successful surgical resection and improved survival in patients with borderline resectable pancreatic cancer.
McClaine RJ; Lowy AM; Sussman JJ; Schmulewitz N; Grisell DL; Ahmad SA
HPB (Oxford); 2010 Feb; 12(1):73-9. PubMed ID: 20495649
[TBL] [Abstract][Full Text] [Related]
25. Poorly differentiated resectable pancreatic cancer: is upfront resection worthwhile?
Crippa S; Partelli S; Zamboni G; Barugola G; Capelli P; Inama M; Bassi C; Pederzoli P; Falconi M
Surgery; 2012 Sep; 152(3 Suppl 1):S112-9. PubMed ID: 22766365
[TBL] [Abstract][Full Text] [Related]
26. Contemporary Reappraisal of Intraoperative Neck Margin Assessment During Pancreaticoduodenectomy for Pancreatic Ductal Adenocarcinoma: A Review.
Datta J; Willobee BA; Ryon EL; Shah MM; Drebin JA; Kooby DA; Merchant NB
JAMA Surg; 2021 May; 156(5):489-495. PubMed ID: 33533898
[TBL] [Abstract][Full Text] [Related]
27. Tumor resectability and response on CT following neoadjuvant therapy for pancreatic cancer: inter-observer agreement study.
Kim HY; Lee YJ; Chang W; Cho J; Park JH; Lee JC; Kim J; Hwang JH; Kim YH
Eur Radiol; 2022 Jun; 32(6):3799-3807. PubMed ID: 35032213
[TBL] [Abstract][Full Text] [Related]
28. Low lymphocyte monocyte ratio after neoadjuvant therapy predicts poor survival after pancreatectomy in patients with borderline resectable pancreatic cancer.
Kawai M; Hirono S; Okada KI; Miyazawa M; Shimizu A; Kitahata Y; Kobayashi R; Ueno M; Hayami S; Tanioka K; Yamaue H
Surgery; 2019 Jun; 165(6):1151-1160. PubMed ID: 30765142
[TBL] [Abstract][Full Text] [Related]
29. Para-aortic node involvement is not an independent predictor of survival after resection for pancreatic cancer.
Sperti C; Gruppo M; Blandamura S; Valmasoni M; Pozza G; Passuello N; Beltrame V; Moletta L
World J Gastroenterol; 2017 Jun; 23(24):4399-4406. PubMed ID: 28706422
[TBL] [Abstract][Full Text] [Related]
30. Locally advanced pancreatic cancer: association between prolonged preoperative treatment and lymph-node negativity and overall survival.
Kadera BE; Sunjaya DB; Isacoff WH; Li L; Hines OJ; Tomlinson JS; Dawson DW; Rochefort MM; Donald GW; Clerkin BM; Reber HA; Donahue TR
JAMA Surg; 2014 Feb; 149(2):145-53. PubMed ID: 24306217
[TBL] [Abstract][Full Text] [Related]
31. Extended neoadjuvant chemotherapy for borderline resectable pancreatic cancer demonstrates promising postoperative outcomes and survival.
Rose JB; Rocha FG; Alseidi A; Biehl T; Moonka R; Ryan JA; Lin B; Picozzi V; Helton S
Ann Surg Oncol; 2014 May; 21(5):1530-7. PubMed ID: 24473642
[TBL] [Abstract][Full Text] [Related]
32. Neoadjuvant strategy as initial treatment in resectable pancreatic cancer: concrete evidence of benefit.
DE Felice F; Musio D; Raffetto N; Tombolini V
Anticancer Res; 2014 Sep; 34(9):4673-6. PubMed ID: 25202043
[TBL] [Abstract][Full Text] [Related]
33. Is Neoadjuvant Therapy Sufficient in Resected Pancreatic Cancer Patients? A National Study.
de Geus SWL; Kasumova GG; Eskander MF; Ng SC; Kent TS; James Moser A; Vahrmeijer AL; Callery MP; Tseng JF
J Gastrointest Surg; 2018 Feb; 22(2):214-225. PubMed ID: 29235000
[TBL] [Abstract][Full Text] [Related]
34. Outcomes after resection of locally advanced or borderline resectable pancreatic cancer after neoadjuvant therapy.
Barugola G; Partelli S; Crippa S; Capelli P; D'Onofrio M; Pederzoli P; Falconi M
Am J Surg; 2012 Feb; 203(2):132-9. PubMed ID: 21824596
[TBL] [Abstract][Full Text] [Related]
35. The prognostic influence of resection margin clearance following pancreaticoduodenectomy for pancreatic ductal adenocarcinoma.
Jamieson NB; Chan NI; Foulis AK; Dickson EJ; McKay CJ; Carter CR
J Gastrointest Surg; 2013 Mar; 17(3):511-21. PubMed ID: 23297028
[TBL] [Abstract][Full Text] [Related]
36. Impact of resection status on pattern of failure and survival after pancreaticoduodenectomy for pancreatic adenocarcinoma.
Raut CP; Tseng JF; Sun CC; Wang H; Wolff RA; Crane CH; Hwang R; Vauthey JN; Abdalla EK; Lee JE; Pisters PW; Evans DB
Ann Surg; 2007 Jul; 246(1):52-60. PubMed ID: 17592291
[TBL] [Abstract][Full Text] [Related]
37. Increased neutrophil-to-lymphocyte ratio after neoadjuvant therapy is associated with worse survival after resection of borderline resectable pancreatic ductal adenocarcinoma.
Glazer ES; Rashid OM; Pimiento JM; Hodul PJ; Malafa MP
Surgery; 2016 Nov; 160(5):1288-1293. PubMed ID: 27450715
[TBL] [Abstract][Full Text] [Related]
38. [Rectum-preserving surgery after consolidation neoadjuvant therapy or totally neoadjuvant therapy for low rectal cancer: a preliminary report].
Huang Y; Huang SH; Chi P; Wang XJ; Lin HM; Lu XR; Ye DX; Lin Y; Deng Y
Zhonghua Wei Chang Wai Ke Za Zhi; 2020 Mar; 23(3):281-288. PubMed ID: 32192308
[No Abstract] [Full Text] [Related]
39. [Short-term outcomes of the TRIANGLE operation after neoadjuvant chemotherapy in locally advanced pancreatic cancer].
Xu D; Tu M; Zhang K; Wu PF; Lyu N; Wang QQ; Yin J; Wu Y; Lu ZP; Chen JM; Xi CH; Wei JS; Guo F; Miao Y; Jiang KR
Zhonghua Wai Ke Za Zhi; 2024 Feb; 62(2):147-154. PubMed ID: 38310383
[No Abstract] [Full Text] [Related]
40. Oral squamous cell carcinoma: histologic risk assessment, but not margin status, is strongly predictive of local disease-free and overall survival.
Brandwein-Gensler M; Teixeira MS; Lewis CM; Lee B; Rolnitzky L; Hille JJ; Genden E; Urken ML; Wang BY
Am J Surg Pathol; 2005 Feb; 29(2):167-78. PubMed ID: 15644773
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
